Nab-paclitaxel Compared With Docetaxel in the Neoadjuvant Chemotherapy Breast Cancer

Exclusion Criteria

• •1. bilateral invasive breast cancer, metastatic disease or other malignant tumors.
• •2. Surgical axillary staging surgery was performed within 6 months before entering the study;
• •3. Pregnant or lactating women; Patients with fertility are unwilling or unable to take effective contraceptive measures;
• •4. before the start of the study, radiotherapy, chemotherapy, biological therapy and / or hormone therapy for the current diagnosis of breast cancer were carried out.
• •5. Patients with central nervous system metastasis or \> grade 1 peripheral neuropathy;
• •6. Patients with severe myelosuppression at the time of screening;
• •7. Patients with severe liver dysfunction (child's class III) or renal dysfunction at the time of screening;
• •8. Other concomitant diseases that the researchers believe are seriously harmful to the safety of patients or will hinder the implementation or completion of treatment plan (such as untreated congenital heart disease, glomerulonephritis, etc.);
• •9. Allergic to albumin for injection, paclitaxel, epirubicin, cyclophosphamide and docetaxel;
• •10. Patients with mental disorders;
• •11. Subjects who are participating in other clinical studies or whose first medication time is less than 4 weeks (or 5 half lives of the study drug) from the end of the previous clinical study (last administration);
• •12. Other situations that may affect the progress of clinical research and the judgment of research results and are not suitable for inclusion in the study.